CANNSUN MEDHEL GROUP PUBLIC LIMITED COMPANY

Cannsun Medhel Group Public Limited Company is a global healthcare organisation that specialises in the development of botanical-based adaptogens, cosmetics and novel drug products. As a vertically integrated bio-ceutical and medical-cannabis company, Cannsun combines clinical research with science-driven product development to deliver innovative solutions for health and wellbeing.

The group's core activities span three pillars. In Research & Development, it conducts clinical trials exploring cannabinoids for schizophrenia, traumatic brain injury and, most recently, a Phase II psilocybin study targeting major depressive disorder in women. Its Medical-Cannabis division manages international export, local patient licensing and a dedicated doctor-patient network via the CannHealth MD portal. The Botanical Wellness arm formulates CBD, CBG and CBN-rich adaptogens, adhering to EUGMP standards for safety and efficacy.

Manufacturing hubs in South Africa, Thailand and Greece support a worldwide supply chain, serving partners across Europe and Asia. By integrating research, production and distribution, Cannsun delivers cutting-edge, evidence-based therapies to patients, clinicians and wellness consumers worldwide.